Microdosing vs SSRIs:
What’s Happening in the Brain and Why It Matters

Secure your spot

Mental illness is rising faster than ever, affecting over 57 million adults in the U.S. each year. In 2021 alone, nearly 29 million SSRI prescriptions were written, making them one of the most common treatment options.

Yet despite their widespread use, SSRIs pose significant challenges—from unwanted side effects to limited effectiveness, especially for those with treatment-resistant conditions.

Enter: microdosing. Over 4 million Americans microdosed psilocybin in 2024. This emerging approach is rapidly gaining momentum as a promising alternative, with neuroscience beginning to uncover how—and why—it may offer new hope.

Join us for a live, expert-led webinar with renowned psychedelic researcher Robin Carhart-Harris, PhD, as we dive into the brain science behind microdosing vs SSRIs—and explore what it could mean for the future of mental health.

  • What brain imaging (PET, fMRI) reveals about SSRIs vs microdosing
  • How psychedelics boost brain connectivity and neuroplasticity
  • Why Default Mode Network flexibility is key to emotional regulation
  • Microdosing’s potential to support depression, anxiety, and PTSD—especially when SSRIs fall short
  • The REBUS model: how psychedelics help unlock stuck mental patterns
  • Real-world implications for individuals and practitioners
  • Where research still needs to catch up—and how you can be part of the movement

Robin Carhart-Harris, PhD

Neuropharmacologist, Psychologist, and Ralph Metzner Distinguished Professor in Neurology and Psychiatry at the University of California, San Francisco.

Paul F. Austin

Co-Founder and Educational Director of Microdosing Collective, Founder of Third Wave and the Psychedelic Coaching Institute.

Alli Schaper

Co-Founder and Community Director of Microdosing Collective, Co-Founder of SuperMush, and Host of Into the Multiverse.

Register anyway for free – we’ll send you the recording!